Clinical Trial Update: Immunogenicity and Safety of ADACEL™ as Fifth Dose in Taiwan [Phase 3]

View source ↗

Summary

Phase 3 trial in Taiwan evaluating immunogenicity and safety of a fifth dose of ADACEL (diphtheria-tetanus-pertussis vaccine); study completed with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Pertussis
• Tetanus

Drugs mentioned

• ADACEL (Tdap vaccine (tetanus, diphtheria and acellular pertussis vaccine))

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Diphtheria, Tetanus | Phase 3 | Status: COMPLETED | Results posted: 2009-06-08